Skip to main content

Table 2 Baseline characteristics and disease activity

From: Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

  Placebo (N = 105) Baricitinib 2 mg (N = 105) Baricitinib 4 mg (N = 104)
Age, years, mean (SD) 44.9 (12.8) 43.2 (11.0) 45.0 (12.4)
Female, n (%) 99 (94.3) 96 (91.4) 99 (95.2)
Time since onset of SLE symptoms, years, mean (SD) 9.7 (7.7) 11.8 (9.1) 11.5 (10.3)
SLEDAI-2K score, mean (SD) 8.9 (2.9) 8.8 (3.4) 9.0 (3.3)
≥1 A or ≥2 B BILAG scores, n (%) 62 (59.0) 56 (53.3) 69 (66.3)
Physician’s Global Assessment scorea, mean (SD) 1.5 (0.5) 1.5 (0.5) 1.6 (0.5)
Positive anti-dsDNA, n (%) 51 (48.6) 56 (53.3) 53 (51.0)
Anti-dsDNA, IU/mL, median (range)b 125.8 (33, 999) 139.8 (35, 1167) 128.4 (31, 1864)
Immunoglobulin G, g/L, median (range)c 13.4 (5.2–53.4) 13.5 (6.3–26.1) 13.0 (6.9–40.6)
Complement C3, g/L, median (range) 1.0 (0.3–1.7) 1.0 (0.4–1.7) 1.1 (0.26–2.0)
Complement C4, g/L, median (range) 0.2 (0.0–0.5) 0.2 (0.0–0.4) 0.2 (0.0–0.9)
  1. Data are presented as mean (standard deviation) unless stated otherwise
  2. a Scores range from 0 to 3 on a visual analogue scale with higher values indicating more severe disease
  3. b Reported for patients with anti-dsDNA ≥30 IU/mL at baseline
  4. c Placebo, n = 101; baricitinib 2 mg, n = 99; baricitinib 4 mg, n = 96)
  5. BILAG British Isles Lupus Assessment Group, C component, dsDNA double-stranded deoxyribonucleic acid, N number of patients, n number of patients in a subgroup, SLE systemic lupus erythematosus, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index-2000